I cam across this a minute ago. It could be old news or already posted but it seems to explain what most of us already thought when it comes to SD and gyno.
UM, if this clogs up the thread too much let me know and I'll delete.
Invalid Link Removed
Q: Why do people get gyno after a cycle of superdrol? Superdrol is non-aromatizing, so there should be no estrogen problem, right? So is it a progesterone thing or something? Also, do you think a SHBG binder is a good thing post-cycle?
A: Superdrol is 2a,17a-dimethyl-5a-androstan-17b-ol-3-one. It is, like you said, a non-aromatizing steroid. Technically speaking, it is a DHT derivative and it is a very potent compound. It can shut your hypothalamic pituitary testicular axis (HPTA) down quite readily and profoundly.
I don?t believe this post-cycle gyno has anything to do with progesterone, as superdrol does not possess any of the structural characteristics associated with progestational steroids. In all likelihood, the post-cycle gyno is an estrogen-related phenomenon brought on by altered androgen/estrogen balance. During the superdrol cycle, the balance of androgens to estrogens in the body is greatly shifted toward androgens, as you are experiencing suppression of estrogen (secondary to testicular shutdown) while simultaneously having a very strong androgen coursing through your system.
Now, of course everything is fine and dandy with estrogen being suppressed and androgen predominating. But what happens when you stop your cycle? The big problem here has to do with the inhibitory effects of androgens upon estrogen receptor expression and what happens when this effect is suddenly eliminated. I am not talking about androgens blocking estrogen receptors; I am talking about androgens interfering with the ability of estrogens to carry out their signal at the genes themselves. In other words, this is a post-receptor phenomenon.
In the post-cycle period, you experience a precipitous drop in androgen levels and therefore a drop in the suppression of estrogen receptor signaling. Now, even though estrogen levels are very low, you are put into a period of exquisite sensitivity to their actions so it?s still a dangerous time. Of course, this is one reason why people resort to the use of estrogen receptor antagonists such as tamoxifen during this time period (the other reason is to help restore endogenous testosterone production).
But eventually, you have to come off the estrogen blockers. We know from the use of agents such as tamoxifen in breast cancer patients who extend use of them that this can actually lead to estrogen hypersensitivity. So unless you have simultaneously raised your testosterone levels up high enough, you are going to be right back in the same boat. At this point, additional use of an aromatase inhibitor might be wise, as it will allow your testosterone levels to continue to recover while keeping the androgen/estrogen ratio in a healthy range. Once a healthy level of testosterone is achieved, then discontinuation should leave you with a normal endocrine balance and estrogen response.
Anyway, the bottom line here is that these people simply did not follow through with their PCT long enough. They underestimated the suppressive potential of the superdrol. Just because something is over-the-counter does not mean it should not be treated seriously.
Now for the second part of your question. SHBG as you know means sex hormone-binding globulin and it is a protein that circulates around in your system and binds to?well?sex hormones. By sex hormones, we mean androgens and estrogens, and I think this is something a lot of people forget (the estrogen part, that is). So SHBG limits the amount of androgen that is bioavailable (which is undesirable), but at the same time it protects us from being overwhelmed by estrogens.
The good news with SHBG is that it binds testosterone and DHT more tightly than it does estradiol, so testosterone and DHT activity is more sensitive to fluctuations in levels of SHBG. This theoretically may allow us to advantageously manipulate the post-cycle endocrinological milieu through the use of natural substances known to be competitive substrates for SHBG (SHBG binders).
My (and once again this is theoretical) way of best incorporating a SHBG binder into post-cycle therapy might be as follows. You start off with a good dose of a selective estrogen receptor modulator (SERM) such as tamoxifen, which should effectively prevent estrogen receptors from being activated by endogenous estrogens. Then after two or three weeks, you add in an aromatase inhibitor for a week or so after which you drop the SERM and continue on the aromatase inhibitor, along with the SHBG for another two to four weeks.
At this time, you hopefully will have re-established a normal level of testosterone along with normal estrogen receptor sensitivity.